EGFR and metastatic colorectal cancer: As lapatinib sensitizes colon cancer cells to EGFR inhibitors or fluoropyrimidines, the combination of lapatinib with standard chemotherapy has been suggested as a new strategy for the treatment of metastatic colorectal cancer [55, 56].